MTOR and hypertriglyceridemia: However, despite these antitumor effects, mTOR inhibitors are rarely given right after solid organ transplantation, because they have been associated with the increased incidence of wound healing complications and severe side effects, including peripheral edema and hypertriglyceridemia.14